Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 3, 2006, Pages 275-281

  Zhou, Xiao Jian ^a   Lloyd, Deborah M ^a   Chao, George C ^a   Brown, Nathaniel A ^a  

^a Idenix Pharmaceuticals Inc   (United States)

Author keywords

Antiviral; Food effect; Hepatitis B; Pharmacokinetics; Telbivudine

Indexed keywords

TELBIVUDINE; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE DISORDER; CALORIC INTAKE; CHOLESTEROL DIET; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; SOMNOLENCE; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DIETARY FATS; DRUG MONITORING; ENERGY INTAKE; FASTING; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; NUCLEOSIDES; PYRIMIDINONES;

EID: 32944455131     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005284849     Document Type: Article

References (23)

1. Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 2001 ; 45: 229-235.
2. Bridges EG, Cretton-Scott E, Zhou XJ, Juodawlkis A, Gosselin G, Bryant ML. The anti-HBV agent β-L-thymidine exhibits no observable effects in chronic developmental toxicity studies [abstract]. Antiviral Res. 2001 ; 84-85. Abstract 85.
3. Bridges EG, Bryant ML, Placidi L, et al. 2001. Toxicological study of the anti-HBV agent β-L-2′-deoxythymidine. In: Schinazi RF Sommadossi JP, Rice CM, eds. Frontiers in Viral Hepatitis. Amsterdam, the Netherlands: Elsevier BV ; 2001: 263-270.
4. Cretton-Scott E, Zhou XJ, Bridges EG, et al. Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine inwoodchucks andmonkeys. Antiviral Ther. 1999 ; 4: A124 - A124.
5. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of oncedaily oral telbivudine (LdT) in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004 ; 40: 719-726.
6. Davey P, Parker S. Cost effectiveness of once-daily oral antimicrobial therapy. J Clin Pharmacol. 1992 ; 32: 706-710.
7. Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of β-L-2′-deoxythymidine and β-L-2′-deoxycydine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother. 2001 ; 46: 1728-1733.
8. Angel JB, Hussey EK, Hall ST, et al. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest. 1993 ; 6: 70-74.
9. Moore KH, Shaw S, Laurent AL, et al. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol. 1999 ; 39: 593-605.
10. Yuen GJ, Lou Y, Thompson NF, et al. Abacavir/lamivudine/ zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. J Clin Pharmacol. 2001 ; 41: 277-288.
11. Unadkat JD, Collier AC, Crosby SS, Cummings D, Opheim KE, Corey L. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS. 1990 ; 4: 229-232.
12. Lotterer E, Ruhnke M, Trautmann M, Beyer R, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol. 1991 ; 40: 305-308.
13. Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol. 1992 ; 33: 657-660.
14. Ruhnke M, Bauer FE, Seifert M, Trautmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1993 ; 37: 2153-2158.
15. Shelton MJ, Portmore A, Blum MR, Sadler BM, Reichman RC, Morse GD. Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy. 1994 ; 14: 671-677.
16. Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999 ; 19: 932-942.
17. Kaul S, Christofalo B, Raymond RH, Stewart MB, Macleod CM. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1998 ; 42: 2295-2298.
18. Emtriva (emtricitabine) [package insert]. Foster City, Calif: Gilead Sciences ; 2004.
19. Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH. Food-induced reduction in bioavailability of didanosine. Clin Pharmacol Ther. 1991 ; 50: 503-507.
20. Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol. 1993 ; 33: 568-573.
21. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002 ; 42: 419-427.
22. Hivid (zalcitabine) [package insert]. Nutley, NJ: Hoffman-La Roche ; 2002.
23. Baraclude (entecavir) [package insert]. Princeton, NJ: Bristol-Myers Squibb ; 2005.